Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
1. RPRX priced $2 billion of senior unsecured notes. 2. Notes include $600M due 2031, $900M due 2035, and $500M due 2055. 3. Net proceeds will be used for general corporate purposes. 4. Closing of the offering is expected on September 16, 2025. 5. RPRX is the largest buyer of biopharmaceutical royalties.